| Systemic Lupus Erythematosus |
1 |
0.98 |
| Lupus |
0 |
0.95 |
| Genomic Medicine |
0 |
0.29 |
| Arthritis |
0 |
0.14 |
| Receptors |
0 |
0.14 |
| Child |
0 |
0.12 |
| Genetics |
0 |
0.12 |
| Rheumatoid Arthritis |
0 |
0.12 |
| Immunology |
0 |
0.1 |
| New York |
0 |
0.1 |
| Autoimmune Disease |
0 |
0.07 |
| Biologic Therapy |
0 |
0.07 |
| COVID-19 |
0 |
0.06 |
| Adverse Effects |
0 |
0.05 |
| Clinical Research |
0 |
0.05 |
| Dermatoses |
0 |
0.05 |
| DNA Sequencing |
0 |
0.05 |
| Healthcare and Medical Technology |
0 |
0.05 |
| Patient Safety |
0 |
0.05 |
| Targeted Cancer Therapy |
0 |
0.05 |
| Viral Infection |
0 |
0.05 |
| Toxicology |
0 |
0.04 |
| CRISPR |
0 |
0.02 |
| Cytokines |
0 |
0.02 |
| Dermatomyositis |
0 |
0.02 |
| Health Care Inequities |
0 |
0.02 |
| Nail |
0 |
0.02 |
| Pathogenesis |
0 |
0.02 |
| Pharmacogenomics |
0 |
0.02 |
| Pollutant |
0 |
0.02 |
| Precision Medicine |
0 |
0.02 |
| Quality of Life |
0 |
0.02 |
| Social Determinants of Health |
0 |
0.02 |